The US Food and Drug Administration announced a pilot program accelerating regulatory review for generic drugs manufactured domestically using US-sourced active pharmaceutical ingredients. This initiative aims to enhance drug supply chain resilience and reduce dependency on foreign manufacturing, aligning with broader governmental efforts to support domestic pharmaceutical production. The program streamlines abbreviated new drug applications (ANDAs), promising faster market entry for eligible generics.